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ABSTRACT 
 
 Retinal hypoxia and inadequate oxygen delivery have been implicated as causal 
for the development of several eye diseases, including diabetic retinopathy, glaucoma, 
and retinopathy of prematurity.  The imaging of oxygen tension in the retina, generated 
from a measure of the phosphorescence lifetimes of bolus-injected palladium-porphyrin 
probes, has been used successfully to study retinal oxygen dynamics in numerous animal 
models.  However, the specific parameters for applying this technique in the mouse have 
not been thoroughly investigated.  The goals of this project were to calibrate a newly-
constructed phosphorescence lifetime imaging instrument and data analysis software 
against known oxygen concentrations, to determine specific parameters for probe 
excitation and image collection and analysis in the mouse eye, and to assess any damage 
caused to the eye by the technique using histological analysis.  An in vitro system was 
developed for calibration of the probe and for estimation of power of excitation light and 
camera settings necessary to produce acceptable oxygen maps.  In vivo experiments were 
then performed, and plots indicating camera settings necessary for producing varying 
qualities of oxygen maps were constructed.  Trypsin digestion of retinal tissue was used 
in an attempt to assess any damage to experimental subjects, but this histological 
technique was deemed inadequate for analyzing the capillary structures of the mouse eye.  
Alternatively, damage was assessed using the instrument itself to calculate changes in 
oxygen tension during the experimental process.  The results of this work will allow the 
phosphorescence lifetime imaging system to be used in the mouse to study how changes 
in retinal oxygen tension correlate with the progression of eye diseases where oxygen is 
implicated, including diabetic retinopathy.  
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1.   INTRODUCTION 
 
 Retinal hypoxia has been implicated as a causal factor in the development of 
numerous eye diseases, including diabetic retinopathy, retinopathy of prematurity, and 
glaucoma.  Recently, a phosphorescence lifetime imaging technique has been developed 
for measuring oxygen tension in the eye that has important implications for the study 
retinal oxygenation in mouse models of these serious diseases.  Optimizing this 
phosphorescence lifetime imaging technique for use in the mouse eye will allow for more 
complete, accurate, and useful studies of the oxygen tension in normal and diseased 
mouse retinas. 
Phosphorescence lifetime imaging has received considerable attention in the 
literature as a method for measuring oxygen tension in vivo [Shonat, 1997].  This 
technique involves the injection of a phosphorescent probe into animal vasculature and 
the subsequent excitation of this probe with light.  From its excited state, the probe 
phosphoresces and can be quenched by oxygen.  The degree of quenching and, hence, the 
concentration of oxygen, can be determined by measuring the phosphorescence lifetime.  
When the excitation light is modulated sinusoidally, the phosphorescence is emitted at 
the same frequency, but with a phase delay resulting from the finite lifetime of the 
phosphorescence.  Using a phase-sensitive detector, such as a cameras image intensifier, 
phase and, therefore, lifetime, can be determined.  Using the intensity of phosphorescence 
reaching the camera at a series of intensifier phase delay values, phase shift maps can be 
created.  When known equations are applied to each pixel in these maps, the phase shift 
maps can be converted to oxygen tension (PO2) maps. 
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Despite the recognition of this technique in the literature [Wilson, 1991 and 
Shonat, 1992, 1997, 1998], the specific parameters for data collection and analysis in the 
mouse eye have not been thoroughly investigated.  The goal of this project was to 
examine these parameters in an effort to optimize the phosphorescence lifetime imaging 
technique for measuring oxygen tension in the mouse retina.  The specific aims for 
achieving the goal of optimization were: 
1.  To calibrate the phosphorescence lifetime imaging system in vitro using a probe 
solution equilibrated at different oxygen concentrations.   
2. To determine appropriate parameters for optimal excitation of the probe, 
including wavelength, bandwidth, energy, and power of the excitation light. 
3. To determine optimal procedures for image collection and analysis, including 
camera exposure time, intensifier gain, and number of images necessary for 
fitting. 
4. To examine, using histological techniques, any potential microvascular damage 
induced by this measurement. 
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2.  BACKGROUND 
Phosphorescence lifetime imaging is the marriage of techniques in physiology, 
imaging, and microscopy.  Understanding its application to the normal or diseased eye 
requires study of eye structure, retinal oxygenation, and the basics of imaging and 
microscopy.  The following sections provide background in these areas, as well as an 
overview of phosphorescence lifetime imaging in general. 
 
Oxygen Delivery and Consumption in the Retina 
The eye is a unique organ requiring a complex vasculature to deliver adequate 
oxygen for visual and neural function, while maintaining visual clarity and transparency.  
Oxygenation in the various parts of the eye, including the retina, reflects the distinctive 
demands of ocular vascularization. 
The retina is located on the back surface of the eye, behind the vitreous.  All 
vertebrate retinas have a layered structure [Dowling, 1987 and Moses, 1987] (Figures 2.1 
and 2.2).  Two synaptic layers, known as the outer and inner plexiform layers, are stacked 
between three cellular layers, termed the outer and inner nuclear layer and the ganglion 
cell layer [Dowling, 1987].  These layers are capped by the pigmented epithelial layer 
and the inner limiting membrane.  The outer nuclear layer contains the cell bodies of the 
photoreceptors, which are sensitive to light and initiate all visual responses in the retina 
and the brain [Dowling, 1987 and Moses, 1987].    The inner nuclear layer contains the 
neuron and glial cell bodies (not shown in the figure), while the ganglion cell layer 
contains the ganglion cell bodies.  The outer plexiform layer is the site of the synaptic 
reactions of photoreceptors, horizontal cells, and bipolar neurons.  The inner plexiform 
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layer houses the synaptic interactions involving bipolar neurons, amacrine cells, and 
ganglion cells [Moses, 1987].   
 
 
Figure 2.1-Cutaway view of retinal layers.  Light enters from the 
front of the retina and travels through the layers to the 
photoreceptors.  Visual information travels from the 
photoreceptors to the bipolar cells and the ganglion cells before 
traveling down the fibers of the optic nerve to the brain [Sherwood, 
2001]. 
 
When light enters the eye, it passes through the retina and is captured by the 
photoreceptors and the outer segments of the pigment-containing cells in the pigment 
epithelium [Dowling, 1987].  Visual processing then occurs in the opposite direction, 
passing through the retina to the optic nerve at the front of the retina.  The fibers of the 
optic nerve then transmit the visual signal to the brain.   
The retina requires adequate amounts of oxygen for normal function 
[Linsenmeier, 1989 and Yu, 2001].  The photoreceptors responsible for collecting light 
and converting it to an electrical signal contain a large concentration of mitochondria,  
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Figure 2.2—The layered structure of the retina [Dowling, 1987]. 
 
necessary for producing energy to carry out this function.  This large production of 
energy makes the retina one of the highest oxygen consuming tissues in the body [Yu, 
2001].  However, the necessity of transparency in the retina limits extensive 
vascularization, and the retina has only a simple vasculature radiating from the optic 
nerve; [Yu, 2001].  This constraint dictates that the extensive oxygen requirements of the 
retina be met in part by adjacent vasculatures.   The avascular parts of the retina, 
including the photoreceptors and the outer regions, are preferentially supplied with 
oxygen by the choroidal vasculature, which lies behind the retina [Delori, 1988 and Yu, 
2001] (Figure 2.1).  This vasculature is characterized by a low vascular resistance and 
high blood flow rate, with an average PO2 very close to arterial PO2 [Linsenmeier, 1989 
and 2000] and significantly greater than the PO2 in the retinal vasculature.   
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 Retinal oxygen consumption is heterogeneous through the different layers of the 
tissue [Yu, 1999].  Oxygen tension is relatively uniform in the inner retina, reaches a 
minimum within the outer retina, and rises to a maximum at the tips of the outer 
segments near the choroid [Linsenmeier, 1986] (Figure 2.2).  In regards to oxygen 
consumption modeling, the avascular outer retina can be broken into three layers:  layer 
1, consisting of the pigment epithelium and outer segments of the photoreceptors; layer 2, 
consisting of the inner segments of the photoreceptors; and layer 3, consisting of the 
outer plexiform layer.  Of these three layers, only layer 2 consumes oxygen, as oxygen-
dependent mitochondria are most abundant in the inner segments of the photoreceptors 
[Linsenmeier, 1986 and 2000].  The oxygen consumption of the other two layers is 
modeled most accurately with values near zero. 
The oxygen demands of the inner retina are supplied directly by the retinal 
circulation.  The retinal circulation differs from the choroidal circulation in terms of flow 
rate and control mechanisms [Linsenmeier, 1986].  There exist two capillary beds in the 
retina, the outer bed being more venous in nature than the inner layer [Alder, 1983].  The 
oxygen tension is relatively low between these two beds [Yu, 1999].  The retinal 
circulation has no autonomic innervation, relying totally on local control mechanisms to 
regulate distribution of blood flow [Alder, 1997].  The capillary system in the retina is 
sparse to allow for minimal optical interference and, as such, has a large arteriovenous 
oxygen difference [Alder, 1997].   
 The high oxygen demands of the retina, along with its delicate supply 
mechanisms, make it more vulnerable to vascular deficiencies than most other organs 
[Yu, 2001].  Neither the retinal nor the choroidal circulation is capable of adequately 
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compensating for impairment to the other [Alder, 1983].  Thus, damage to either the 
retinal or choroidal vasculature can be devastating, often resulting in complete loss of 
vision [Yu, 2001].  Problems with retinal oxygen supply are often treated with panretinal 
photocoagulation.  This technique, in which a laser is applied to broad areas of the retina, 
destroys photoreceptors in the peripheral retina and is thought to increase the oxygen flux 
from the choroid to the inner retina and thereby compensate for a decrease in retinal 
circulation.  Less oxygen is consumed in the partially burned outer retina, allowing for 
increased oxygen supplied to the inner retina [Stefansson, 1981].   
 
Oxygen Measurements in the Eye 
 Many different techniques have been developed for measuring oxygen tension in 
the eye.  However, most of these techniques have significant limitations, particularly in 
applications to the small mouse eye.   
 Oxygen-sensitive microelectrodes have been used extensively in animal models 
for generating oxygen profiles in the eye.  While their use has offered many insights into 
ocular oxygenation, this method is highly invasive; the insertion of the electrode into the 
eye and the subsequent withdrawal of the electrode with oxygen tension measurements 
taken at specified points can cause significant trauma.  Each introduction of the electrode 
offers only a one-dimensional oxygen profile for the region of insertion.  Electrodes must 
also be recalibrated following each profile measurement.  The invasive nature of the 
microelectrode prevents its ready application in clinical settings (due to the necessity of 
surgical intervention), or to mice (due to the small size of the eye) [Ito, 2001].   
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 Retinal vessel oximetry has been used in humans to determine oxygen saturation 
of blood [Delori, 1988].  This technique is based on the fact that the light absorbing 
properties of blood (absorbance spectrum) depends on the amount of oxygen bound to 
hemoglobin.  While the technique may be used to accurately determine oxygen tensions 
under ideal conditions, measurements are adversely affected by a number of factors 
including eye pigmentation, turbidity of ocular media, and irregular retinal topography 
[Delori, 1988].  It is also an indirect measure of oxygen tension. 
MRI-based methods have also been used to survey oxygen characteristics of the 
retinal surface [Ito, 2001].  This method is unhindered by optical properties and eye size, 
but it requires the use of a perfluorocarbon droplet situated in the preretinal vitreous 
space, thus limiting its application in human subjects. 
Light-based methods for exploring oxygen tensions in the eye have gained recent 
prominence.  Some fluorescent and phosphorescent compounds (see Fig. 2.4) have been 
discovered to be sensitive to oxygen; when oxygen collides with a light-emitting 
compound in its excited state, it quenches the molecule and prevents light emission.  The 
use of fluorescence to determine PO2 is limited due to relatively low sensitivity of 
fluorescent molecules to oxygen [Vanderkooi, 1987]; fluorophores remain in the excited 
state for a relatively short period of time (nanoseconds to microseconds), and thus have 
limited opportunity to collide with oxygen molecules, particularly at low PO2s.  Changes 
in turbidity of the suspending medium also affect fluorescence measurements.  In 
contrast, phosphorescent probes are not affected by blood flow, and have relatively long 
lifetimes (microseconds to seconds), thereby increasing the likelihood of collision with 
oxygen molecules in the blood. 
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Imaging and Microscopy 
Standard research microscopes and low power objectives can be used for viewing 
the small mouse eye and its vasculature.  Major parts of the microscope optical train 
include the light source, a dichromatic beam splitter (for fluorescence and 
phosphorescence microscopy), the objective lens, the ocular, and the camera or 
observers eye (Figure 2.3).  An image is produced and focused to infinity by the  
 
Figure 2.3-Optical train of a microscope.  The specimen is 
illuminated by one of the light sources, and the image of the 
specimen travels along the optical train to the camera and/or the 
observer’s eye. 
 
objective lens conjugate with the specimen.  A very high quality, diffraction-limited 
image is produced with a modern, high-numerical aperture plan-apochromatic objective 
Dichromatic mirror 
and tube lens 
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lens [Inoue, 1997].  A tube lens then focuses the image onto a target.  When a charge-
coupled device (CCD) camera is used, that target consists of a large array of photodiodes 
deposited on a silicon substrate.  Each sensor element on the CCD camera is a silicon 
photodiode built into the silicon chip, isolated electrically from its neighbors by a channel 
stop [Inoue, 1997].  The image may also be projected to the eye. 
 
Phosphorescence Lifetime Imaging of Oxygen Tension 
Phosphorescence lifetime imaging has been recognized in the literature as a 
technique for measuring oxygen tension in the vasculature [Wilson, 1991 and Shonat, 
1992, 1997, 1998].  This technique can be applied to determine oxygen tensions in the 
mouse retina and in such a case is based on excitation of a phosphorescent probe and 
subsequent quenching of phosphorescence by intravascular oxygen.  The probe is bolus-
injected intravenously, and equilibrates in the bloodstream.  It may then be excited by 
light delivered through the eye.  When excited, the probe molecules phosphoresce, and 
are quenched when they collide with oxygen molecules.  The frequency of collision and, 
hence, the oxygen concentration, may then be determined by computing the lifetime of 
the phosphorescence decay.  The probe remains exclusively in the vasculature in the eye 
due to the blood-retinal barrier. 
The phosphorescent probe generally used is palladium meso-tetra [4 
carboxyphenyl] porphrine.  This probe is sensitive to oxygen in physiological 
concentrations when bound to excess albumin.  It is excited at 422 and 524 nm, and emits 
phosphorescence at 698 nm, a wavelength in the near-infrared range where the retinal 
tissue absorbs minimally [Shonat, 1992 and Lo, 1996].   
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Phosphorescence lifetime imaging requires a unique microscopic instrument 
(Figure 2.4).  An illuminating beam is emitted by a xenon arc lamp, sinusoidally 
modulated using an optical chopper, and a particular wavelength (524 ± 20 nm) is 
selected by a monochromator.  The light is then low-pass filtered and reflected down into 
the objective by a dichromatic mirror (pass>575 nm).  This light excites phosphorescent 
molecules in the vasculature to their triplet states, and phosphorescence is emitted during 
the decay of these molecules back to the ground state.  This emitted light then passes  
 
Figure 2.4-The phosphorescence lifetime imaging system.  White 
light is emitted by the xenon arc lamp and sinusoidally modulated 
by the optical chopper.  The monochromator selects a particular 
wavelength of light, which is directed to the eye by a dichromatic 
mirror.  Phosphorescence is produced by probe in the eye, and 
travels to the CCD camera. 
 
 
straight through the dichromatic mirror to the intensifier, which amplifies the relatively 
weak phosphorescent signal before transmitting it to the CCD camera.  The intensifier is 
also used for the phase-sensitive detection of phosphorescence lifetimes, which will be 
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explained below.  The image is then conducted to the PC-based image analysis system.  
This technique represents one of the few modes of microscopy in which the illuminating 
excitation wavelength differs from the wavelength of emitted light [Inoue, 1997].  Due to 
the relative weakness of the emitted light, high-sensitivity photodetectors and high light-
gathering optics are required.  These include objectives with high numerical aperture-to-
magnification ratios and high transmission for the relevant wavelengths [Inoue, 1997].   
Phosphorescence is defined as the emission of light during a transition from an excited 
triplet state to the ground state.  The energy diagram in Figure 2.5 illustrates this 
phenomenon.  The three singlet states (ground, first, and second) are depicted by S0, S1, 
and S2, respectively.  In each of these states, the molecule may exist in a number of 
vibrational energy levels, indicated by 0, 1, 2, etc. [Lakowicz, 1999].  Photons are 
depicted by lightning bolts.  The vertical lines represent possible transitions between 
states, illustrating the instantaneous nature of light absorption.   
When a fluorescent or phosphorescent molecule absorbs a photon, it is excited to 
a higher vibrational level of S1 or S2.  Fluorophores then rapidly relax to the lowest 
vibrational level of S1, a process called internal conversion (Figure 2.4) [Lakowicz, 
1999].  The molecule will then return to the ground state at any of the vibrational energy 
levels, quickly relaxing to the lowest level.  During the decay to the ground state, the 
molecule emits of photon in the form of fluorescence. 
Excitation to the triplet state (T1) involves a spin conversion from the S1 state, 
resulting in a state with unpaired spinsa phenomenon termed intersystem crossing 
(Figure 2.4) [Turro, 1978 and Lakowicz, 1999].  In this excited state, the two electrons 
are each in a different orbital, and thus the Pauli exclusion principle does not require their 
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Figure 2.5—Energy diagram for fluorescent and phosphorescent 
molecules.  S0, S1, and S2, depict ground, first, and second singlet 
states, respectively.  T1 depicts the triplet state.  Each state has 
representative vibrational states indicated by 0, 1, and 2.  Solid 
vertical lines arrows represent transitions between states, dashed 
arrows represent vibrational relaxation within states, and lightning 
bolts represent photons.  A molecule is excited from the ground 
state to any of the vibrational levels of the singlet state, and then 
decays to the lowest vibrational state in S1.  Fluorescent molecules 
will then decay down to the ground state with the emission of 
fluorescence, with a total reaction time on the order of ns to µs.  
Phosphorescent molecules undergo a spin flip to the triplet state, 
then decay to the ground state with a spin flip and 
phosphorescence emission, with a total reaction time of the order of 
µs to s.  Once in the ground state, molecules will relax to the lowest 
energy level (0).  Adapted from Lakowicz, 1999 and Vanderkooi, 
1990. 
 
 
spins to be paired.  The energy required to produce this excited state is determined by the 
equation 
∆E = E2  E1 = hυ 
where h is Plancks constant, υ is the frequency of the excitation light, and E2 and E1 are 
the energies of a single molecule in the initial and final states [Turro, 1978].  Like the 
singlet state, the triplet state is a metastable species, and will decay to the ground state 
after a finite time, emitting a photon in the form of phosphorescence.  However, the 
decay from the triplet state takes a relatively long time (microseconds to seconds) when 
S2 
S1 
T1 
S0 0 
1 
2 
Absorption 
Internal 
conversion 
Fluorescence
Phosphorescence 
Intersystem 
crossing 
(spin flip) 
Vibrational
relaxation 
spin 
flip 
Vibrational
relaxation 
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compared with decay from the singlet state (nanoseconds to microseconds) due to the 
quantum mechanically forbidden spin flip completed during the decay.   
When a large number of phosphorescent molecules are excited simultaneously, 
the resultant light emission is the sum of the individual photon emissions, and can be 
represented by the function: 
I(t) = I0exp(-t/τ) 
where I(t) is the phosphorescence intensity as a function of time (t), I0 is the initial, 
maximum intensity at t = 0, and τ is the lifetime of the decay [Shonat, 1995].   
In phosphorescence the excitation and emission wavelengths differ, and neither is 
exact; the numerous possible vibrational states create a range of wavelengths that may be 
absorbed or emitted, with a relative maximum wavelength resulting from conversions 
between the most common states.  The excitation spectrum for palladium meso-tetra [4-
carboxyphenyl] porphrine, the phosphorescent probe used in this study, has maxima at 
420 and 524 nm. Due to the absorption of excitation light by blood, the volume of 
excitation, defined as the excitation area times the penetration depth, is ten times smaller 
at 420 nm than at 524, and the total quantity of probe excited is reduced [Shonat, 1995].  
The emission is maximal at 687 nm, regardless of what wavelength is used for excitation; 
decay always occurs from the lowest vibrational level of the triplet state resulting in a 
consistent emission spectrum [Lo, 1996 and Vanderkooi, 1990].    
 When the phosphorescent probe is excited by light that has been sinusoidally 
modulated, the phosphorescence emitted will have the same frequency, but will have 
lower amplitude and be delayed in phase by an angle θ.  θ is related to the probe lifetime, 
τ, by the following equation: 
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tan θ = ωτ 
where ω is the excitation frequency [Shonat, 1997]. 
 A phosphorescent molecule that has been excited to the triplet state may transfer 
its energy to another molecule without light emission, a phenomenon termed quenching 
(Figure 2.6).  Such interactions between phosphors and their environment are common; 
the spin-forbidden transition from the triplet state to the ground has a relatively long 
lifetime, and increases the probability of contact between molecules [Vanderkooi, 1990].   
 
 
 
 
 
Figure 2.5—Quenching of the phosphorescent probe by oxygen.  
6When the two molecules collide, the decaying probe gives its 
energy to oxygen instead of giving it off as phosphorescence.  This 
results in a singlet oxygen molecule, which decays to the ground 
state within microseconds. 
 
 
In blood, the only significant quenching agent is oxygen [Wilson, 1991].  The 
degree of quenching of the phosphorescent molecule depends on the concentration of 
oxygen in its vicinity [Shonat, 1992].  The efficiency of phosphorescence quenching is 
governed by the frequency of collision between the excited triplet state molecule and the 
quencher before the phosphor returns to the ground state.  This relationship is represented 
by the Stern-Volmer equation: 
τo / τ = 1 + kQτ0[PO2] 
S1 
T1
S0 
Absorption 
S0 
Probe S1 
Oxygen
Collision
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where τo is the lifetime in the absence of oxygen, kQ is the bimolecular rate constant (or 
quenching constant), and [PO2] is the oxygen concentration [Vanderkooi, 1987, Shonat, 
1995 and 1997, and Lo, 1996].  In a zero oxygen environment, τ = τo and the lifetime is a 
maximum.   
 Quenching reactions form excited singlet oxygen (Figure 2.5), which may react 
with unsaturated double bonds in lipids to form peroxides.  These peroxides destructively 
alter amino acids and nucleic acids.  However, destruction of biological tissue by these 
reactions is mitigated by the fact that singlet oxygen decays to the ground state within 
microseconds, and any chemical reactions must occur by collision with the singlet-state 
molecule before it decays [Vanderkooi, 1987].  However, the potential for vascular 
damage must always be considered when using these probes for in vivo applications. 
Palladium meso-tetra porphrine must be mixed with excess albumin prior to 
injection for phosphorescence quenching studies.  This complex has several properties 
essential to accurate phosphorescence lifetime imaging: the sensitivity to quenching of 
albumin-bound probe by oxygen is independent of the suspending medium or probe 
concentration in solution, self-quenching of the probe is eliminated, and the sensitivity to 
oxygen is increased since the binding to albumin decreases kQ [Vanderkooi, 1987 and 
Shonat, 1995].  As long as albumin is present in excess of the probe, the probe/albumin 
complex may be suspended in saline and injected directly into the femoral vein, and will 
show no decrease in phosphorescence intensity over several hours [Wilson, 1991].   
 Calibration of the probe for determining oxygen concentration in the vasculature 
is absolutecalibration depends only on the phosphor and its molecular environment, 
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which remain constant for such experiments [Lo, 1996].  Once τ0 and kQ are known ex 
vivo, they apply in vivo and recalibration is not necessary [Vanderkooi, 1987].   
From phosphorescence lifetime, PO2 can be calculated. A phase-sensitive 
measure of this phosphorescence lifetime is possible when the delivered excitation light 
and the sensitivity of the collection system (intensifier) can be independently modulated 
and the phase relationship between these two elements can be accurately varied [Shonat, 
1997].  Intensity images may then be taken with increasing intensifier phase delays 
relative to excitation phase, and a graph of intensity versus phase delay constructed.   
This graph may be used in conjunction with the following equation to determine the 
phosphorescence phase delay, θ: 
I(θD) = k[Pd]{1+  mDmcos(θ - θD)} 
 
where Ι(θD) is the intensity as a function of known phase delay, k is a constant, [Pd] is the 
probe concentration, θD is the phase delay of the intensifier sensitivity, mD is the 
modulation of the emission, and  
m = (1 + ω2τ2) -1/2. 
However, since this equation is nonlinear, applying it to each pixel in an image is 
computationally difficult.  A linearized form of the equation was developed by Lakowicz 
[1992] by applying the trigonometric identity for subtraction of cosine terms and 
combining the fitting parameters into linear coefficients: 
I(θD) = a0 + a1cosθD + b1sinθD   
where a fit to the equation can be determined by the evaluation of a0, a1, and b1 using 
linear regression.  θ is then determined as: 
tan-1(b1/a1) 
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and may be used to determine τ for each pixel.  This value of τ is used in the Stern-
Volmer equation to calculate PO2 maps (Figure 2.7). 
 
 
Figure 2.7—Maps of the mouse retina.  The PO2 map (A) is created 
using the Stern-Volmer equation.  The parameters for the equation 
are calculated by fitting a series of intensity images to a linear 
equation (B shows the R2 for this fit in every pixel), which is used to 
determine phase shift (D).  Phase shift is then used to calculate 
lifetime (C). 
 
Certain hardware and software elements and an electronic interface are required 
for the generation of PO2 maps (Figure 2.8).  The program used for data collection,  
A B
C D
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Figure 2.8—Schematic diagram of the phosphorescence lifetime 
imaging system.   
 
WinViewNT (Roper Scientific, Trenton, NJ), allows for control of the digital delay 
generator (Stanford Research Systems, Sunnyvale, CA) and the camera and its intensifier 
(Roper Scientific, Trenton, NJ).  The delay generator sets the phase delay of the 
intensifier relative to the optical chopper.  The optical chopper controller (Photon 
Technology, Brunswick, NJ) rotates the chopper disc at 1.6 kHz, and sinusoidally 
modulates the light produced by the Xenon arc lamp.  The light passes through a 
monochromator (Photon Technology), which selects the wavelength used for excitation 
(524±20 nm).  A shutter (Vincent Associates, Rochester, NY), which is directly 
connected to the camera control mechanism, operates in parallel with the camera, 
opening only during camera exposure and blocking the excitation light when the camera 
shutter is closed.  The light passes through a focusing lens and an interference filter, is  
reflected off a dichromatic mirror, and is concentrated by an infinity-corrected objective 
to reach the retinal plane [Shonat, 1992 and 1995].  Light emitted from the eye is 
collected by the objective and sent to the dichromatic mirror, where wavelengths longer 
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than the cut-off wavelength of 630 nm pass through to the intensifier to the CCD camera 
[Shonat, 1992].  The camera delivers each image to the WinViewNT program, where the 
entire series may be stored as a single binary data file. 
Advantages of phosphorescence lifetime imaging of oxygen tension are 
numerous.  Recalibration of the probe is not required.  The response time is very short, 
and signal acquisition and calculation are rapid.  Data analysis is also relatively simple, 
since the dependence of phosphorescence lifetime on oxygen pressure follows a well-
defined physical relationship, which can be expressed with simple equations [Lo, 1996].   
Difficulties with the phosphorescence lifetime imaging technique mainly involve 
the possible effects of the excitation on the tissue.  The excitation of the phosphorescent 
probe within the blood vessels of the eye and subsequent quenching by oxygen creates 
oxygen free radicals, which are toxic to the vessels and tissue.  Extensive excitation of 
the probe decreases the amount of oxygen available to the eye, and can cause significant 
damage.  To limit tissue damage, the concentration of the probe and the duration of 
exposure to excitation light should be kept to a minimum [Shonat, 1995]. 
To utilize the phosphorescence lifetime imaging system to its fullest potential, the 
existing structure was calibrated using an in vitro system to ensure that oxygen maps 
report accurate PO2 values.  Acquisition parameters, including camera exposure time, 
intensifier settings, power of excitation light, and number of images necessary for 
determining phase shift were determined for in vivo experiments.  Histological techniques 
were used in an attempt to assess any microvascular damage induced by the 
measurement. 
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3. METHODS 
Despite its potential usefulness in the characterization of oxygen tensions in 
diabetic retinopathy and other oxygen-related eye diseases, the specific parameters for 
phosphorescence lifetime imaging in the mouse eye have not yet been determined.  The 
primary goal of this project was to determine these parameters.  To this end, in vitro and 
in vivo experiments were conducted, and appropriate gains, exposure times, and other 
imaging considerations were examined. 
 
Data Acquisition and Analysis 
 Phosphorescence intensity images were collected using the WinViewNT software 
package (see Background).  For each data set, a series of 15 to 30 images was taken at 
increasing phase delays, and stored as a single binary data file. Data analysis for all in 
vitro and in vivo experiments was done using Microsoft Excel, SigmaPlot, and a program 
in MatLab called Retina, developed by Ross Shonat (see Appendix B).   
 Three experiments at each gain and exposure time were performed.  Map R2 
values, indicating the fit to the equation I(θD) = a0 + a1cosθD + b1sinθD,  were used as an 
indication of the quality of the oxygen maps.  PO2 means and standard deviations for 
specified regions were calculated using the Retina program. 
 
In Vitro Experiments 
An in vitro system was constructed to calibrate the phosphorescence lifetime 
imaging system and to determine approximate gain settings and exposure times required 
to produce acceptable oxygen maps.  The system, pictured in Figure 3.1, included a  
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Figure 3.1—In vitro system.  The system consists of an oxygenator 
connected to a gas mixer, a peristaltic pump used for circulating 
probe solution inside the system, and a square glass capillary tube 
situated under the microscope objective used for measuring the 
PO2 of the solution.  The parts are connected with Tygon 
microbore tubing, which may be disconnected at various junctions 
and injected with solution using a 22-gauge needle and syringe. 
 
length of Tygon tubing, into which a probe solution, consisting of 12 ml albumin stock 
solution, 148 mg NaCl, 216 mg glucose, and 10 µl probe was injected.  A peristaltic 
pump was used to circulate the fluid through the system.  The phosphorescent solution 
flowed through an oxygenator (consisting of a length of plastic tubing, inlaid with a 
Plexiglas rod wrapped with oxygen-permeable silastic tubing, and capped at each end by 
a rubber stopper with an inlet connector for the gas mixer and an outlet for exhaust), used 
to apply gas mixtures with known oxygen concentrations.  Upon leaving the oxygenator, 
Peristaltic 
pump Glass capillary 
tube 
Oxygenator
Connection 
to gas mixer 
Microscope 
objective 
Exhaust
Direction 
of flow 
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the solution flowed through a square glass capillary tube situated under the 
phosphorescence lifetime imaging system.  The phosphorescence lifetime was then 
measured as previously described, and a PO2 map was generated.  The correspondence 
between the PO2 values indicated by the map and those applied using the gas mixer and 
oxygenator was used to calibrate the system to provide accurate measures of PO2 within 
the vasculature.   
 Signal-to-noise ratios (SNR) were used to determine appropriate gain settings and 
exposure times.  The probe was equilibrated at a physiological oxygen concentration of 
40 mm Hg (5% oxygen applied using the gas mixer and oxygenator).  Exposure times 
were tested at random in an attempt to achieve a maximal range of SNR for camera 
intensifier gain settings 10, 100, and 255.  Exposure times yielding SNR of 
approximately 2 and approximately 225 were noted for each gain.  Phosphorescence 
lifetime images were then taken at a range of ten exposure times equally spaced between 
the time yielding SNR ≈ 2 and the time yielding SNR ≈ 225.  R2 maps, which 
demonstrate the integrity of the fit between the phosphorescence intensity data and the 
equation I(θD) = a0 + a1cosθD + b1sinθD, were then created.  From these maps, the average 
R2 value for the entire capillary tube was determined.  These values were plotted versus 
SNR for each gain setting  
The in vitro system was also used to calibrate the phosphorescence lifetime 
imaging system against known oxygen concentrations.  Oxygen concentrations in the 
physiological range of zero to 100 mm Hg were tested.  To obtain concentrations in this 
range, the oxygenator was used to apply gas mixtures between one and 12 percent O2 
balanced with N2.  A zero oxygen environment was obtained by adding probe solution 
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and a pinch of glucose oxidase to a closed cuvette to prevent leakage of environmental 
oxygen into the system (Figure 3.2).  At each oxygen concentration, ten image sets were 
taken at each of four gain settings (100, 70, 40 and 10).  Exposure times were 0.23, 0.47, 
0.83, and 1.0 seconds, respectively, and were selected based on the fact that they yield 
SNRs between 3 and 15.  After each exposure, the objective was blocked with white 
paper to produce intensity images with a theoretical phase delay of zero and a modulation 
of one (reflected images).  These data were used to determine the intrinsic phase delay 
and modulation of the instrument. 
 
 
Figure 3.2—Zero-oxygen in vitro testing system.  Cuvette is filled 
with glucose-containing probe solution, to which glucose oxidase is 
added to remove all oxygen.   
 
 
 
In Vivo Oxygen Mapping 
All animal experiments were performed in accordance with WPIs Institutional 
Animal Care and Use Committee (IACUC) protocols and the Association for Research in 
Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision 
Research.   Mice were anesthetized prior to all experiments with a solution of 125 µl  
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Avertin and 4.875 ml saline, in the amount of 0.25 ml/10 g body weight (adjusted as 
needed).  When fully anesthetized, one eye per mouse was dilated with Mydriacyl (1%).  
Mice were fixed in a stereotaxic head holder (Figure 3.3) to prevent movement and assist 
placement during experimentation.  A drop of Goniosoft ophthalmic ointment was placed 
on the dilated eye, and a small piece of microscope coverglass was situated on top of the 
layer of Goniosoft to negate the refractive power of the cornea.   
 
 
Figure 3.3—Stereotaxic head holder.  Mouse rests on a heated 
platform, designed to maintain body heat while animal is under 
anesthesia.  The mouthpiece is inserted into the animal’s mouth, 
and the nosepiece is tightened onto the nose with the tension knobs.  
The rotational knobs are loosened to allow proper positioning of 
the head so the eye may be viewed, and tightened to prevent 
movement once the proper position is achieved. 
 
Probe solution was introduced through the femoral vein by venous puncture.  A 
small patch of skin was removed above the vessel, and a solution of 10 mg/ml Pd meso-
tetra [4-carboxyphenyl] porphrine in bovine serum albumin was bolus injected in the 
amount of 10 mg/kg body weight1.  Following injection, the vein was cauterized to 
                                                 
1 Dosages of 5 mg/kg and 15 mg/kg were also tested; however, the lower dose yielded relatively faint 
intensity images, while the higher dose resulted in damage to the retinal vessels with relatively little light 
exposure.     
Nosepiece 
Heated 
platform 
Mouthpiece
Rotational  
knobs 
Tension 
knobs
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prevent bleeding.  The mouse was then placed under a dissecting microscope, and the 
position of the head was adjusted such that the retinal blood vessels radiating from the 
optic nerve were visible.  Power density of the excitation light (mJ/cm2) was measured 
prior to data collection using a photodetector and power/energy meter (Newport 
Corporation, Irvine, CA).   
Eight mice, labeled 1a-8a, were prepared and tested at gains 10, 40, 70, and 100, 
as determined by the in vitro experiments.  Exposure times were selected based on 
preliminary in vivo tests; times yielding signal-to noise ratios between 3 and 15 without 
exceeding 1.0 second were used (Table 3.1).  Fifteen images per set, determined during in 
vitro experiments to be adequate, were taken beginning with an intensifier delay of 5 µs 
and continuing at 20 µs increments.  Experiments were performed in triplicate for each 
gain and exposure time setting.  The sequence of data collection was varied in each 
mouse (see Appendix E).   
 
Gain Exposure Times (seconds) 
100 0.6, 0.145, 0.23, 0.315, 0.4 
70 0.15, 0.31, 0.47, 0.63, 0.79 
40 0.32, 0.49, 0.66, 0.83, 1.0 
10 0.4, 0.55, 0.7, 0.85, 1.0 
Table 3.1—Gain settings and exposure times used for in vivo 
experiments. 
 
 
 Regions of interest in a vein, an artery, and a section of tissue were then selected 
for each mouse.  The Retina program (Appendix B) was used to analyze these different 
and distinct regions.  A maximum PO2 of 150 was used in the analysis, and all pixels 
exceeding this value were rejected as physiologically impossible.  The following 
parameters were noted for each region: 
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• Fitting parameters a0, a1, and b1 
• Phase shift (θ) 
• Modulation (m) 
• PO2 mean and standard deviation 
• R2 mean and standard deviation 
• Number of pixels in the selected region of interest 
• Number of pixels from the selected region of interest used for calculations 
Signal-to-noise was calculated as a0 (the DC fitting term) divided by the average intensity 
with the microscope objectives shutter closed (camera dark noise).  Accumulated energy 
deposition at each point in the experiment was calculated as excitation light power 
(measured with a power/energy meter) divided by excitation light area multiplied by 
cumulative exposure time.  The analysis was then repeated using a smaller number of the 
images (7), beginning with the first and continuing with every other image in each set to 
maintain uniform phase delay increments. 
 
Histology 
Histology was used as a potential method for determining any damage to the 
mouse eye incurred during phosphorescence lifetime imaging, and, potentially, as a 
method for correlating physical damage caused by disease with the PO2 maps.  No 
standard technique for conducting histology on the mouse retina exists, so the assistance 
of Dr. Robert Frank of the Kresge Eye Institute, Wayne State University, Detroit, MI, 
was sought.  His expertise in performing trypsin digestion and periodic acid solution 
(PAS)/hematoxylin staining on rat retinas was well known, and personal communication 
with him and personnel in his lab indicated that this technique could be successfully 
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applied to the mouse retina.  A visit to his lab allowed the intricacies of the technique to 
be learned, and a protocol for conducting trypsin digestion and PAS/Hematoxylin 
staining on the mouse retina was developed (see Appendices C and D).   
To induce damage following in vivo calibration experiments, probe-injected (10 
mg/kg) mice were exposed continuously to 524 nm excitation light for an extended 
period of time on a single eye.  Following continuous exposure for an hour, mice were 
removed to a dissecting microscope.  Complete retinal vascular damage was confirmed 
by the absence of blood flow in retinal vessels (vessels appearing white in color, rather 
than the normal red).  Eyes were removed and retinas were digested and stained, with the 
non-exposed eye serving as a control.   
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4. RESULTS 
Phosphorescence Intensity 
 Phosphorescence intensity images were acquired, and graphs of intensity vs. 
phase delay created for each in vitro and in vivo experiment.  Sample data appears in 
Tables 4.1 and 4.2, and sample images and curves appear in Figures 4.1 and 4.2.   
Image 
Number 
Phase Delay 
(Radians) 
Intensity 
Average 
Intensity 
Standard Dev. 
2 14.4 941 213 
3 25.9 975 222 
4 37.4 987 224 
5 49.0 985 224 
6 60.5 980 224 
7 72.0 950 218 
8 83.5 923 212 
9 95.0 886 203 
10 106.6 840 194 
11 118.1 788 184 
12 129.6 719 170 
13 141.1 665 159 
14 152.6 604 146 
15 164.2 549 134 
Table 4.1—Sample data for in vitro image set. 
 
Image 
Number 
Phase 
Delay 
(Radians) 
Artery 
Intensity 
Average
Artery 
Intensity 
St. Dev. 
Vein 
Intensity 
Average
Vein 
Intensity 
St. Dev. 
Tissue 
Intensity 
Average 
Tissue 
Intensity 
St.Dev. 
2 14.4 655 30 1150 114 372 32 
3 25.9 654 41 1164 121 370 28 
4 37.4 640 31 1165 119 357 29 
5 49.0 619 35 1135 112 342 31 
6 60.5 594 29 1106 109 323 28 
7 72.0 564 30 1052 105 302 267 
8 83.5 532 27 1008 102 279 24 
9 95.0 482 30 936 98 254 22 
10 106.6 444 29 878 94 228 20 
11 118.1 403 24 810 82 202 20 
12 129.6 353 22 730 80 178 16 
13 141.1 325 24 655 73 155 16 
14 152.6 275 16 589 63 134 13 
15 164.2 248 19 522 57 118 12 
Table 4.2—Sample data for in vivo image set.
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Figure 4.1—Sample intensity images and intensity vs. phase delay 
graph for in vitro experiments.  Intensity images corresponding to 
phase delays of 25°, 95°, 25°, and 164°, are shown.  The region of 
interest used for intensity averaging is indicated by the red line in 
each image.  The maximum value on the graph, corresponding to 
the phase delay, and used to calculate PO2, is also indicated.
25° 95° 164° 
θ=24° (PO2=22 mm Hg)  
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Figure 4.2—Sample intensity images and intensity vs. phase delay 
graph for in vivo experiments.  Intensity images corresponding to 
phase delays of 25°, 95°, 25°, and 164°, are shown.  The region of 
interest used for intensity averaging is indicated by the red region 
in each image—vein, artery, and tissue were selected for each 
animal tested.  The maximum value on the graph, corresponding to 
the phase delay, and used to calculate PO2, is also indicated. 
 
 
In Vitro Tests 
 The phosphorescence lifetime imaging system was calibrated using the in vitro 
testing system, described in the methods section.  Early experiments identified a drift in 
the optical chopper phase, which was rectified with a change in hardware.  Experiments 
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with a blocked objective and no phosphorescence verified that the instrument did not 
produce significantly different results at different gains, exposure times, or total 
experiment times.  However, an intrinsic phase error of 0.80 and modulation error of 0.67 
were discovered.  The phase error was subtracted from all subsequent data sets, and the 
modulation error was divided.   Following this correction, PO2 and R2 maps (where R2 is 
a measure of the fit of the intensity images to the specified equation) were created for 
each image set, a sample of which appears Figure 4.3, and a final calibration curve was 
generated (Figure 4.4). 
 To determine if map fit was affected by intensity signal-to-noise ratio, average R2 
value for the capillary tube was plotted versus SNR (with SNR calculated as the average 
intensity of images taken at a series of 30 delay settings between 10 and 300 µs divided 
by the average intensity of images taken with no light entering the camera).  The results 
appear in Figure 4.5.  
 
 
Figure 4.3—Sample PO2 and R2 maps for in vitro experiments.  
Regions of interest selected for data analysis in the “Retina” 
program are delimited by the blue lines. 
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Figure 4.4—In vitro calibration curve.  The x-axis represents 
oxygen concentrations applied with the gas mixer.  The y-axis 
indicated PO2 as determined by the phosphorescence lifetime 
imaging system.  A line of identity intersects the data, indicating 
that the system produced accurate PO2 maps. 
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Figure 4.5—Average R2 value versus SNR for gain settings 10, 100, 
and 255.  Gain 255 gave less than acceptable R2 values regardless of 
signal-to noise ratio.  Gains 10 and 100 yielded very high R2 values 
at SNR>50. 
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 These data indicate that a gain setting of 255 did not produce images with 
acceptable R2 values (>0.9), even at high signal-to-noise ratios.  In contrast, R2 values of 
greater than 0.9 were obtained with gain settings 10 and 100 for all SNR > 50.  These 
results were verified in subsequent experiments (data not shown).  As a result, all 
subsequent experiments were conducted at gain settings between 10 and 100.  Since the 
data indicated that all SNR>50 yield similarly high R2 values, exposure times resulting in 
signal-to-noise ratios of 50 or less were used, thereby minimizing excitation light 
exposure.   
 
In Vivo Tests 
 For all image sets with 15 images each, a vein, an artery, and a section of tissue 
were analyzed (Figure 4.6).  In general, PO2 was highest in the tissue region, and lowest 
in the veins.  For each of these regions, graphs were created for R2 vs. SNR, PO2 vs. 
accumulated energy deposition, and PO2 vs. SNR.  The raw data for each animal appear 
in Appendix E, and sample data and graphs for a single mouse (Mouse 1a) are shown in 
Table 4.3 and Figure 4.7.   Figure 4.8 contains summary plots of R2 vs. signal-to-noise 
ratio for the three regions in all mice.  Each data point represents an individual image set.   
For all regions, lower gains produced better fits at lower signal-to-noise ratios.  
All gain settings yielded R2 values of approximately 0.95, but a gain setting of 100 
requires an SNR of greater than 10 to produce this good fit.  Conversely, a gain setting of 
10 requires an SNR of only 4 to produce an excellent fit.  However, it must be considered 
that achieving an SNR 4 at gain 10 requires an exposure time of 1.0 seconds, while 
achieving an SNR of 10 at gain 100 requires an exposure time of only 0.4 seconds.  
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Figure 4.6—Sample PO2 and R2 maps for in vivo experiments.  
Regions of interest for vein (top), artery (bottom) and tissue 
(center) are indicated by the blue lines.   
 
 
Gain 
Exposure 
Time 
Relative 
Image 
Number 
Cumulative 
Image 
Number 
Accumulated 
Energy 
Deposition 
(mJ/cm^2) SNR 
PO2 
Mean 
PO2 St. 
Dev 
R2 
Mean
R2 St. 
Dev 
100 0.06 1 1 4.5 3.1 31.3 25.5 0.71 0.11 
100 0.06 2 2 9.1 3.1 33.2 24.6 0.70 0.12 
100 0.06 3 3 13.6 3.1 39.4 29.7 0.72 0.11 
100 0.145 1 4 24.6 6.6 37.3 22.3 0.86 0.06 
100 0.145 2 5 35.6 6.2 38.1 23.5 0.85 0.06 
100 0.145 3 6 46.6 5.9 35.2 20.7 0.85 0.06 
100 0.23 1 7 64.1 8.9 40.2 22.2 0.90 0.04 
100 0.23 2 8 81.5 8.4 39.4 21.6 0.91 0.04 
100 0.23 3 9 99.0 8.3 37.7 19.5 0.90 0.04 
100 0.315 1 10 122.8 11.7 36.4 16.2 0.93 0.03 
100 0.315 2 11 146.7 11.1 40.4 20.7 0.93 0.03 
100 0.315 3 12 170.6 10.7 43.4 19.4 0.93 0.03 
100 0.4 1 13 200.9 14.4 37.0 14.1 0.98 0.03 
100 0.4 2 14 231.3 14.2 37.1 14.4 0.95 0.02 
100 0.4 3 15 261.6 13.0 39.7 17.0 0.94 0.02 
70 0.15 1 16 273.0 2.7 47.8 30.2 0.83 0.07 
70 0.15 2 17 284.4 2.6 44.2 28.1 0.84 0.07 
70 0.15 3 18 295.7 2.6 39.0 25.3 0.84 0.07 
70 0.31 1 19 319.2 4.3 41.2 20.9 0.91 0.04 
70 0.31 2 20 342.7 4.2 43.5 22.8 0.91 0.04 
70 0.31 3 21 366.2 4.3 41.4 22.2 0.91 0.04 
70 0.47 1 22 401.9 5.8 41.7 18.6 0.94 0.03 
70 0.47 2 23 437.5 5.6 43.4 19.4 0.94 0.03 
70 0.47 3 24 473.2 5.8 43.6 20.2 0.94 0.03 
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70 0.63 1 25 520.9 7.1 44.5 17.8 0.95 0.02 
70 0.63 2 26 568.7 7.0 46.1 20.9 0.95 0.02 
70 0.63 3 27 616.5 7.3 47.8 19.1 0.95 0.02 
70 0.79 1 28 676.4 8.5 46.4 18.0 0.96 0.02 
70 0.79 2 29 736.3 8.3 46.9 20.6 0.96 0.02 
70 0.79 3 30 796.2 8.6 41.7 15.2 0.96 0.02 
40 0.32 1 31 820.4 2.4 42.1 24.5 0.88 0.05 
40 0.32 2 32 844.7 2.5 44.2 26.1 0.89 0.05 
40 0.32 3 33 869.0 2.4 47.2 26.5 0.89 0.05 
40 0.49 1 34 906.1 3.1 41.2 20.9 0.92 0.04 
40 0.49 2 35 943.3 3.1 46.8 24.3 0.92 0.03 
40 0.49 3 36 980.4 3.0 48.4 25.6 0.92 0.04 
40 0.66 1 37 1030.5 3.7 45.5 22.2 0.95 0.03 
40 0.66 2 38 1080.5 3.9 43.4 18.8 0.94 0.03 
40 0.66 3 39 1130.6 3.7 45.9 20.9 0.94 0.03 
40 0.83 1 40 1193.5 4.3 48.0 20.9 0.95 0.02 
40 0.83 2 41 1256.4 4.4 44.8 21.1 0.95 0.02 
40 0.83 3 42 1319.4 4.4 45.3 19.3 0.95 0.02 
40 1 1 43 1395.2 5.2 45.1 18.3 0.96 0.02 
40 1 2 44 1471.0 5.1 42.4 16.3 0.95 0.02 
40 1 3 45 1546.9 5.2 44.0 18.1 0.96 0.02 
10 0.4 1 46 1577.2 1.8 42.3 24.6 0.86 0.06 
10 0.4 2 47 1607.5 1.9 44.6 26.7 0.87 0.05 
10 0.4 3 48 1637.9 1.9 45.6 27.3 0.86 0.06 
10 0.55 1 49 1679.6 2.1 43.8 22.8 0.90 0.04 
10 0.55 2 50 1721.3 2.1 38.2 19.7 0.90 0.04 
10 0.55 3 51 1763.0 2.1 42.9 23.9 0.90 0.04 
10 0.7 1 52 1816.1 2.4 42.3 21.3 0.91 0.04 
10 0.7 2 53 1869.1 2.5 40.6 21.4 0.92 0.03 
10 0.7 3 54 1922.2 2.4 44.4 21.3 0.92 0.04 
10 0.85 1 55 1986.7 2.6 43.8 21.1 0.93 0.03 
10 0.85 2 56 2051.1 2.8 41.7 19.7 0.93 0.03 
10 0.85 3 57 2115.6 2.8 43.3 20.2 0.93 0.03 
10 1 1 58 2191.4 3.0 43.5 20.2 0.94 0.03 
10 1 2 59 2267.2 3.1 45.1 19.5 0.94 0.03 
10 1 3 60 2343.0 2.9 46.1 20.9 0.94 0.03 
 
Table 4.3—Sample raw data for in vivo experiments, from Mouse 
1a vein.  Data were calculated from PO2 and R2 maps and intensity 
images using the “Retina” program. 
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Figure 4.7—Sample graphs of in vivo data, taken from Mouse 1a 
vein.  Panel A represents a typical graph of R2 value vs. SNR, 
where R2 value increases slightly with increasing SNR.  Panel B 
shows a typical map PO2 vs. accumulated energy deposition graph, 
where the slope of the trendline is not statistically different from 
zero in the negative direction (one-tailed Student’s t-test, p>0.05). 
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Figure 4.8—Map R2 value versus SNR in vein, artery, and tissue 
for all animals tested.  Each point represents an individual image 
set and R2 map.   
 
Composite graphs of PO2 vs. accumulated energy deposition and vs. signal-to-
noise were not created, as differences in oxygen tensions in individual mice made such 
general comparisons inappropriate.  However, graphs of these parameters for individual 
mice appear in Appendix E.  For all animals, the slope of the linear best-fit lines on these 
plots is not significantly different from zero in the negative direction (one-tailed 
Students t-test, p>0.05), indicating that PO2 was not affected by increasing energy 
deposition or SNR. 
 Results of analysis of image sets with seven images were compared to those 
obtained with 15 images to determine if fewer images (which would result in decreased 
light exposure and less possible physiological damage) could produce accurate maps.  A 
parameter termed Delta PO2, defined as the PO2 calculated with 15 images minus that  
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Figure 4.9—Delta PO2 versus image number for Mouse 4a.  PO2 differs by 
as much as 17 mm Hg when calculated with the fewer number of images, 
indicating that seven images are too few for calculating PO2 accurately. 
 
 
Mouse Vessel Average Delta PO2 Delta PO2 St.Dev.
1 Vein -0.6 3
1 Artery 2.1 3.9
1 Tissue 5.7 3.3
3 Vein 3.7 2.8
3 Artery 7.1 2.5
3 Tissue 9.8 1.8
4 Vein 7.7 3.1
4 Artery 7.9 3.3
4 Tissue 11.3 3.6  
Table 4.4—Summary of delta PO2 mean and standard deviation for Mice 1a, 3a, and 4a.  
Delta PO2 is significantly different from zero in most cases, indicating that the use of seven 
images does not produce accurate PO2 values. 
 
calculated with seven, was used to examine possible error incurred using fewer images.  
Sample results appear in Figure 4.9 and Table 4.4.  PO2 differed significantly when 
 41
calculated with seven images in some cases, indicating that seven images is too few for 
calculating accurate PO2 values. 
Histology 
Trypsin digestion and PAS/Hematoxylin staining (see Appendices C and D) were 
performed on mouse eyes visibly damaged by light exposure, and on unexposed control 
eyes from the same mouse.  No apparent differences were observed between the two 
types of retinas during the digestion procedure, with the exception that the photoreceptors 
of the damaged retinas appeared darker in color than those of the controls. 
Trypsin digestion of the mouse retina proved to be an extremely difficult, lengthy, 
and frustrating process with little reproducibility.  The retinas often did not digest 
completely, requiring extensive mechanical dissection to remove the inner limiting 
membrane and cellular debris, often resulting in damage to the vessel bed.  Digesting for 
longer periods in an attempt to correct this problem resulted in the dissolution of the 
entire retina, including the vasculature.   A mounting of the entire, intact vascular bed 
onto a slide was never accomplished. 
Even somewhat successful digestions, in which large sections of the vasculature 
were mounted onto slides, yielded questionable results when stained (Figure 4.10).  
While the photographs in the first row appear to show flatter, denser arteries and veins in 
the damaged eye (panel B) when compared with the control (panel A), this phenomenon 
cannot be seen in the second or third rows (photographs of different mice).  The large, 
dark blue areas in these photographs represent sections of cellular debris that were not 
cleared away.  As is evident in the pictures, these sections interfere with visualization of 
the vessels, particularly the capillary beds.  However, removing such debris was often 
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impossible without destroying the vessels themselves.  While it may be stated that the 
large vessels in eyes exposed to large amounts of excitation light had a flatter appearance 
than those of their unexposed counterparts, the evidence is largely inconclusive.  
Additionally, no apparent changes in the capillary structure are visible. 
As faulty technique may have been responsible for the poor quality of the mounts, 
the procedure was also performed on a healthy rat retina.  Trypsin digestion of the rat 
retina is a widely accepted procedure, yielding excellent results when performed 
properly.  Results of this digestion appear in Figure 4.11.  The entire vascular bed was 
successfully mounted in nearly intact form, and the capillary structure is more clearly 
visible at high magnification.  The success of this digestion indicates that faulty technique 
is not the cause of the poor quality of the mouse digests. 
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Figure 4.10—Trypsin digestion slides of control (left column) and 
damaged (right column) mouse retinas.  The damaged retina in 
panel B appears to have lost some of its structural integrity when 
compared with its control in panel A—the large vessels appear 
flatter, and the nuclei (blue stain) appear denser within the vessels.  
However, the same direct comparison is not possible in the 
subsequent panels due to damage to the retinal vessels incurred 
during dissection, and dark staining of the cellular debris not 
removed during the trypsin digestion procedure. 
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Figure 4.11—Trypsin digestion of the rat retina, viewed at 4x (A), 
10x (B), and 20x (C) magnification.  The vessel bed is nearly intact, 
and the capillaries are significantly more visible when compared 
with the mouse digests (Figure 4.1). 
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5. DISCUSSION 
 
Significance of Results 
 The first aim of this project was to calibrate the phosphorescence lifetime imaging 
system against known oxygen concentrations.  This was achieved using the in vitro 
calibration system, shown in Figure 4.1.  For the physiologic range of oxygen 
concentrations, the instrument and data analysis program produce accurate PO2 maps.    
 The second aim of determining optimal parameters for probe excitation was 
achieved during in vivo experiments.  Wavelength and bandwidth of 524±20 nm, as 
recommended in the literature, yielded acceptable maps.  A decrease in PO2 was used as 
an indicator of vessel damage; vessels damaged using this technique demonstrate a 
decrease in blood flow, which would subsequently decrease PO2. Setting energy and 
power to keep accumulated energy deposition below 2500 mJ/cm2 prevented damage in 
the eye, as analyzed using observation of vessels and lack of a decrease in average PO2 
over the course of image collection.   
Qualitatively, the relationship between PO2 values in the different regions 
analyzed (vein, artery, and tissue) made logical sense.  The physiological structure of the 
retina, with the high-PO2 choroidal vasculature lying behind the lower-PO2 retinal 
vasculature, caused some interference in phosphorescence images.  In the major blood 
vessels, the light-absorbing properties of hemoglobin prevented the excitation light from 
reaching the probe within the choroidal vasculature, so the true PO2 of the retinal vessels 
was determined.  However, this effect was reduced in the capillary beds, which lie in the 
tissue sections analyzedthe excitation light was allowed to reach the choroid, and 
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phosphorescence was emitted from this oxygen-rich vasculature, yielding high PO2 map 
values.   
 Relationships between camera exposure time, intensifier gain, and the quality of 
oxygen maps was also achieved with in vivo experiments.  Signal-to-noise ratios of 
phosphorescence intensity images were determined to be dependent on camera intensifier 
gain settings.  Low gain settings yielded better fits, and, therefore, better oxygen maps at 
lower signal-to-noise ratios, but at the cost of longer exposure times.  When creating 
oxygen maps, the quality of the maps necessary must be weighed against the ability of 
the eye to withstand lengthy exposure to excitation light, the effect of longer exposure 
times on total experiment time, and the necessity for following rapid physiological 
changes. 
 The minimum number of images necessary to produce acceptable oxygen maps 
was determined to be near 15.  Using 15 intensity images at incremented phase delays 
produced fits comparable to those obtained using 30 images.  Seven images proved to be 
too few, as the delineation between vessels in the oxygen maps grew faint. 
 It was not possible to determine the level of damage caused by experimentation 
using trypsin digestion.  This histological technique did not allow for viewing of the 
capillary structure in sufficient detail to analyze damage to vessel walls.  The inability to 
see any changes in the capillary structure in retinal vasculatures that are decisively 
damaged renders trypsin digestion an unacceptable method for study of the mouse eye.   
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Future Work 
 Additional in vitro calibration studies should be performed to explain the 
variation in instrument PO2 readings for identical applied oxygen concentrations.  While 
the calibration curve shows relatively good correlation between instrument and applied 
oxygen, additional experiments may identify areas for improvement.  Some non-linearity 
in the calibration curve may be present, and must be accounted for. 
 Data from three individual mice (2a, 6a, and 7a) were not included in summary 
analyses due to inadequate physiological control during experimentation.  Likely changes 
in blood pressure and respiration rate during the course of experiments caused variations 
in intensity images, and, hence, inadequate sine-wave fits and poor oxygen maps.  Such 
problems may have been prevented by a physiological control system to monitor blood 
pressure, ensure adequate respiration, and continuously maintain level of anesthesia.  
Implementing such a system will increase efficiency of experiments by allowing for 
greater frequency of experimental success.   
 Experiments determining the threshold of accumulated energy deposition for 
damage to retinal blood vessels would be beneficial.  In this study, no experiments were 
carried out in which damage to blood vessels occurredall animals maintained blood 
vessel structure and oxygen levels.  Determining the level of light exposure needed to 
cause damage would allow for recommendations for maximum light exposure levels to 
be made.  Additionally, the issue of excitation light modulation frequency was not 
addressed.  Changes in modulation frequency could cause significant changes in quality 
of oxygen maps, and should be investigated.  
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 Further analysis of the number of images necessary for creating good quality 
oxygen maps would be beneficial.  It was determined that seven images are too few for 
producing accurate maps when compared with results using 15 images; however, 
numbers between seven and 15 were not examined.  Additional in vivo experiments using 
different image numbers would allow the determination of the absolute minimum number 
of images necessary for accurate maps, and possibly allow for a decrease in light 
exposure to animals during experiments.   
 As trypsin digestion proved to be an unacceptable method for histologically 
examining the mouse eye, other methods should be investigated.  Changes in capillary 
structure are of particular interest in diabetic retinopathy, a disease whose first clinical 
signs manifest in these minute vessels.  The lack of capillary definition in the 
photographs shown in Figure 4.5 makes it unlikely that trypsin digestion and 
PAS/Hematoxylin staining will be of use in further mouse model study.  Laver et al 
[1993] confirm that while retinal mounts of the type used in this study demonstrate the 
microaneurysms present in diabetic retinopathy, they did not provide a clear view of the 
capillaries.  They also claim that, even under ideal conditions, it is difficult to obtain good 
quality trypsin digestions of mouse retinas.  Cuthbertson et al [1986] also verify this 
claim.  Both of these studies recommend the use of elastase, rather than trypsin, for 
digesting the mouse retina.  Analysis of eyes subjected to the phosphorescence lifetime 
imaging technique using elastase digestion and staining may be of benefit.   
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Conclusions 
 The specific aims for achieving the goal of optimization of the phosphorescence 
lifetime imaging system for the mouse eye were calibration of the system, determination 
of probe excitation parameters, determination of image collection and analysis 
parameters, and examination of microvascular damage using histology.  Calibration was 
accomplished using an in vitro system to correlate instrument-derived oxygen tensions 
with known concentrations.  Probe excitation parameters were studied indirectly through 
the determination of accumulated energy deposition during series of phosphorescence 
lifetime imaging experiments.  Image collection and analysis parameters were studied in 
depth, with the final determination that lower intensifier gains produced better maps at 
lower signal-to-noise ratios, but higher gain settings allowed reasonably good maps to be 
created with shorter exposure times.  Gain and exposure time settings for specific 
experiments may be determined using the graphs in Figure 4.8 as a guide.  Seven was 
determined to be too few images for creating clear, precise oxygen mapsthe number 
necessary is closer to fifteen.  The aim of using histology to examine damage caused by 
probe excitation was not achieved, but recommendations for performing this procedure 
more effectively were made. 
 This work demonstrates that the phosphorescence lifetime imaging 
instrumentation and technique may be used for studying oxygen tensions in the mouse 
eye.  The determination of the optimal parameters for conducting such experiments will 
allow for the investigation of how changes in retinal oxygen tensions correlate with the 
progression of numerous ocular diseases, such as diabetic retinopathy, retinopathy of 
prematurity, and glaucoma. 
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Appendix A: Pd-Meso-Tetra (4-carboxyphenyl) Porphrine Probe Solution  
 
1. Measure 50mg Pd-meso-tetra (4-carboxyphenyl) porphrine (Porphryin Products, 
Logan, UT) in a 1.5 ml microcentrifuge tube. 
 
2. Add 500 µl 0.5N NaOHprobe dissolves in basic solution. 
 
3. Warm under tap water until dissolved.  Centrifuge. 
 
4. Make a 1.25x albumin salt solution (25 ml) 
a. Weigh 253.8 mg NaCl (FW = 58.44). 
b. Add distilled/deionized water to 25 ml. 
c. Pour salt water into a wide-mouth container, ad stirring rod and place on 
magnetic stir plate. 
d. Add 1.88g albumin, bovine fraction V (Sigma, St. Louis, MO), taking care 
not to let the albumin touch the sides of the container. 
e. Stir gently to dissolve (takes a few hours). 
 
5.  Slowly mix 4 ml albumin salt solution and all of the probe/NaOH solution. 
 
6. Adjust pH to 7.4 with Tris(hydroxymethyl)aminomethane base (Aldrich Chemical 
Company, Milwaukee, WI) and HCl as needed.  If albumin precipitates, pH is too 
low and Tris should be added. 
 
7. Aliquot into 100 µl portions and store at -20°C. 
 
8. Final solution is Pd-porphyrin (10 mg/ml) in BSA (60 mg/ml) 0.9% NaCl (Shonat 
2001). 
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Appendix B: “Retina” Program 
 
The front panel of this program accepts as inputs τo, kQ, modulation frequency and pulse 
time of excitation light, the name of the file containing the series of intensity images, and 
the number of intensity images to be used for fitting.  It also allows the user to input a 
phase error, which is subtracted from the calculated phase delay, and a modulation error, 
which is divided into the calculated modulation.  Averaging filters may be applied using 
the Phos Filter box.  A region of interest (ROI) may then be selected within the 
intensity images, and a graph of phosphorescence intensity versus phase shift may be 
calculated and fit to the equation I(θD) = a0 + a1sinθD + b1cosθD.  The parameters θ, τ, and 
[PO2] are calculated (see Background), and the fitting parameters k, mD, m, and R
2 are 
also output.  The program may also be used to create a number of maps using the 
intensity images, including PO2 and R2 maps.  The mapping function also allows ROI 
selection, and outputs the mean, standard deviation, maximum, and minimum values 
within the ROI. 
 
 
 
Figure B.1—“Retina” front panel.  Phosphorescence intensity 
image files are input using the “Get” button.  Individual images 
used for graphing and mapping are selected at the bottom of the 
panel—in this particular case, image #1 is not selected.  The 
mapping parameters may be input using the PC keyboard.  Once 
all parameters are correct, the “Show Intensity Images” and 
“Calculate Maps” buttons may be used. 
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Figure B.2—“Show Intensity Images” screen.  Individual intensity 
images may be viewed using the buttons at the top of the screen.  
An ROI may be selected by pressing one of the buttons at the 
bottom, and using the mouse to define a region on the image—the 
ROI selected in this image appears in blue.  A graph of intensity 
versus phase delay for the ROI may be created by pressing the 
“Graph Region” button. 
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Figure B.3—“Graph Region” screen.  Phosphorescence is plotted 
versus phase delay for the images and ROI selected.  Relevant 
fitting and calculated parameters are output on the right.  The blue 
line represents the curve maximum, which indicates the 
phosphorescence phase delay (θ) also output on the right. 
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Figure B.4—“Calculate Maps” screen.  A number of different 
maps may be created using the pull-down menus at the top.  
Filtering parameters may be input to reduce extraneous pixels in 
the images.  Statistics are output in the right center of the screen. 
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Appendix C: Procedure for Trypsin Digestion of the Retina 
 
Note:  All procedures should be performed in a clean, dust-free environment to prevent 
contamination of samples.  Procedures on the eye and retina should be performed under a 
dissecting microscope when necessary. 
 
1. Remove eyes from animal and fix in 10% buffered formalin for a minimum of 5 
days and a maximum of 10-12 days.  After 10-12 days, transfer eyes from the 
fixative into phosphate-buffered saline and store at 4°C. 
 
2. Prepare trypsin digestion buffer: 
a. Weigh out 18.2 g Tris base (MW 121). 
b. Add approximately 800 ml deionized water. 
c. Create a 0.2 M NaF (MW 42) solution using the following formula to 
determine the weight of NaF to be added: 
 
42 x (volume of tris/water solution in L) x 0.2 = weight of NaF in grams 
 
d. Add this measured weight of NaF to the tris/water solution. 
e. Bring this solution to pH 7.8 using concentrated HCl. 
f. Store refrigerated. 
 
3. Prepare trypsin digestion solution: 
a. Weigh out 0.3 g crude trypsin 1:250 powder (it is absolutely necessary to 
use crude trypsinpure trypsin will not digest the retina). 
b. Add trypsin digestion buffer to make 10 ml.  Shake or vortex to 
completely dissolve the trypsin in the buffer. 
c. Centrifuge or filter the solution to remove the sediment. 
d. Either make this solution fresh each day, or aliquot 5-10 ml portions and 
store frozen. 
 
4. Transfer eyes to a 50-ml beaker of distilled water.  Change the water once by 
carefully pouring the water out of the beaker (do not pour out the eyes), and 
refilling the beaker. 
 
5. Place one eye in a petri dish filled with distilled water, and remove excess tissue 
from around the eyeball. 
 
 
6. Place the eye in a sized tray to hold it in place, and use a razor blade to make a 
small initial cut just below the limbus, as indicated on the diagram below: 
 
 62
 
 
 
7. Beginning at the initial cut, use tweezers and scissors to completely remove the 
anterior segment from the eyes, leaving only a cup containing the retina: 
 
 
 
8. Return the eye to the water-filled petri dish, and pop out the lens with a sweep of 
curved scissors or forceps. 
 
9. Hold the sclera (the outside cup of the remaining eyeball) with a pair of forceps, 
and use curved scissors or forceps to carefully free the retina from the eye.  Take 
care not to tear the retina during this process.  The sclera may be cut to facilitate 
removal of the retina.   
 
10. Use an appropriately sized piece of glass tubing with a pipet bulb on the end to 
aspirate the retina and transfer it to a 50-ml beaker of distilled water.   
 
11. Allow the retina to soak for 1-2 hours, changing the water 4 or 5 times.  Take care 
not to pour the retina down the drain when changing the water. 
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12. Transfer the retina to a glass test tube (NOT plasticthe retina will stick to it) 
using the Pasteur pipette, and remove the water with a dropper.  Add 5-10 ml 
trypsin digestion solution to the test tube.  Place the tube in a 37°C shaker water 
bath at 40-60 cycles per minute. 
 
13. Allow the retina to digest for and hour and a half to an hour and forty-five 
minutes.  Diseased or damaged retinas may take longer to digest.  Avoid over-
digestionthis will cause the vessels in the retina to fall apart.  If under-digested, 
the retina may be returned to the trypsin solution for further digestion. 
 
14. Transfer the retina to a petri dish of distilled water with the Pasteur pipette.  Do 
not throw away the trypsin solution.  Three layers of the retina should be visible: 
the jelly-like inner limiting membrane (which is clear, and may not be visible 
unless the petri dish is agitated), the clear/whitish vascular layer, and the tan 
photoreceptor layer.  Grasp the inner limiting membrane with forceps, and use 
scissors to free it from the retina.  The membrane will be sticky and difficult to 
deal with.  Be sure all of this membrane is removed, and wipe it away from the 
forceps on a paper towel. 
 
15. Use a Pasteur pipette with an eyelash cemented to the tip to beat the 
photoreceptors away from the retina.  Use the curved surface of the eyelash, never 
the tip, as the tip may damage the blood vessels.  Continue manipulating the retina 
with the eyelash to remove all cellular debris, frequently dipping the eyelash in 
the trypsin solution to prevent it from sticking to the retina.   
 
16. Once all debris is removed, the vasculature will remain.  It will be nearly 
transparent.  Place a microscope slide in a separate petri dish, and fill the dish 
with enough water adequately cover the slide.  Aspirate the retinal vessels and 
deposit them on the slide.  Using the eyelash, carefully unfold the vessels and 
very gently press them onto the slide.  If necessary, cut the vessels so they lie flat.  
Slowly remove the water from the petri dish using a peristaltic pump set a low 
speed.   
 
17. Allow the vessels to air-dry overnight. 
 
18. Mount and stain the retinas using the Procedure for Hematoxylin Staining of 
Trypsin Digests. 
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Appendix D:  Procedure for Hematoxylin Staining of Trypsin Digests 
1. After mounting retinas onto slides, allow to air-dry overnight. 
 
2. Prepare periodic acid solution: 
a. Weigh out 0.8 g reagent grade periodic acid. 
b. Add 20 ml distilled water.  Agitate to dissolve. 
c. Add 10 ml 0.2M sodium acetate. 
d. Add 70 ml 95% ethanol (66.5 ml EtOH + 3.5 ml water). 
e. Swirl to mix.  Make this solution fresh each day it is used.  Store 
refrigerated when not in use. 
 
3. Place slides in slide staining tray.   
 
4. Stain the slides with the following solutions by using one reagent bottle for each 
step.  Pour the reagent into the staining tray, allow to sit for the specified time, 
and then return the reagent to the bottle (except where specified).   
a. 70% ethanol5 minutes 
b. Periodic acid solution5 minutes 
c. 70% ethanol, 3 changes (3 reagent bottles)2 minutes each 
d. Rinse in distilled water (discard water) 
e. Schiffs reagent25 minutes (Schiffs reagent is light sensitive.  Place 
slides in a drawer or other dark area when soaking in this reagent.) 
f. Running tap water20 minutes 
g. Hematoxylin10 minutes (Hematoxylin is light sensitive.  Place slides in 
a drawer or other dark area when soaking in this reagent) 
h. Running tap water20 minutes 
i. 95% ethanol, 3 changes2 minutes each 
j. 100% ethanol, 3 changes2 minutes each 
k. Xylene, 3 changes2 minutes each 
l. Drop Permount or Histoclad onto each stained retina and apply a cover 
glass. 
 
Vessel walls will appear magenta, and nuclei will be blue. 
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Appendix E: Data Tables and Graphs 
 
 The following are Microsoft Excel spreadsheets used for analysis of data obtained 
during in vivo experiments.  Data are organized by animal number and vessel type, and 
listed in the order images were taken.  Map R2 vs. SNR graphs were not created for 
Mouse 6a because the animal died during experimentation, and insufficient data were 
acquired at each gain setting to allow for statistical significance.  The data from this 
mouse are not included in the summary graphs in the Results section.  Additionally, data 
from Mice 2a and 7a are not included, as excessive head movement and drastic changes 
in the blood flow during image acquisition prevented the creation of satisfactory oxygen 
maps 
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Appendix F: ARVO Abstract 
 
The following abstract was submitted to the Association for Research in Vision and 
Ophthalmology, and accepted for poster presentation at the 2002 Annual Meeting, May 
5-10.  A travel grant was also awarded. 
 
IMAGING OF OXYGEN TENSION IN THE MOUSE RETINA 
 
PURPOSE 
Retinal hypoxia and inadequate oxygen delivery have been implicated as causal for the 
development of several eye diseases, including diabetic retinopathy, glaucoma, and retinopathy of 
prematurity. The imaging of oxygen tension (PO2) in the retina, generated from a measure of the 
phosphorescence lifetimes of bolus-injected palladium-porphyrin probes has been used 
successfully for nearly a decade to study retinal oxygen dynamics in the cat, miniature pig, and 
monkey; however, the specific parameters for applying this technique in the mouse have not been 
thoroughly investigated. As the number of transgenic and knockout mouse models displaying 
characteristics of human retinal diseases rapidly increases, an ability to image PO2 in these very 
small eyes will likely be of great benefit. In this study, we investigate the refinement of a 
technique for generating PO2 maps in the mouse retina using our recently constructed 
phosphorescence lifetime imaging system. 
 
METHOD 
To accurately measure retinal PO2 in this animal, it was necessary to optimize a number of 
important acquisition parameters, including excitation power, intravascular probe concentration, 
camera exposure time, and camera intensifier gain settings. Measurements were made using both 
an in vitro calibration system and in vivo experiments in mice. Appropriate ranges for the stated 
parameters were determined using relationships between camera signal-to-noise values and the 
coefficient of determination (R2) generated from the least-squares analysis used to produce the 
PO2 maps. 
 
RESULTS 
R2 decreased with increasing intensifier gain (at the same signal-to-noise ratio), with the highest 
gain setting for the camera (255) producing unacceptable fits. Intensifier gain settings of 10 and 
100 yielded R2 values above 0.90 with exposure times of 440 ms and 43 ms, respectively. Thus, 
moderate intensifier gain (near 100) reduced exposure time dramatically without significantly 
affecting the fits. The determined ranges for these parameters are currently being applied to the in 
vivo experiments, where excitation power and intravascular probe concentration will also be 
varied to study the effects of probe excitaiton on mouse retinal physiology. 
 
CONCLUSION 
Determination of these parameters will allow a more efficient and effective method for creating 
oxygen maps in the mouse retina. Investigation of how changes in retinal oxygen tension 
correlate with ocular disease progression in cases where abnormalities in the delivery and 
consumption of oxygen are thought to be contributing factors, such as diabetic retinopathy, will 
then be possible. 
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Appendix G: Sigma Xi MS Research Award Executive Summary 
 
The following executive summary was submitted to the Worcester Polytechnic 
Institute Chapter of Sigma Xi, the Scientific Research Society, in nomination for their 
annual MS Research Award.  The project was granted the award for 2002. 
 
Introduction and Specific Aims 
Retinal hypoxia has been recognized as a causal factor in the development of numerous eye 
diseases, including diabetic retinopathy, retinopathy of prematurity, and glaucoma.  An ability to measure 
oxygen tension non-invasively in the eye would significantly advance our understanding of oxygens role 
in these diseases.  Recently, a phosphorescence lifetime imaging technique has been developed in the 
laboratory of Ross Shonat for measuring oxygen tension in the eye, and has important implications for the 
study of retinal oxygenation in mouse models of all of these serious diseases.  It will be used specifically at 
WPI to study diabetic retinopathy.   
While the phosphorescence lifetime imaging technique has become recognized in the literature, 
the specific parameters for data collection and analysis in the mouse eye have not been thoroughly 
investigated.  This goal of this project was to examine these parameters in an effort to optimize the 
phosphorescence lifetime imaging technique for measuring oxygen tension in the mouse retina.  The 
specific aims for achieving the goal of optimization were: 
5. To calibrate the phosphorescence lifetime imaging system in vitro using known oxygen 
concentrations 
6. To determine appropriate parameters for optimal excitation of the probe, including energy and 
power of the excitation light 
7. To determine optimal procedures for image collection and analysis, including camera exposure 
time and intensifier gain 
 
Background 
Phosphorescence lifetime imaging is the marriage of techniques in physiology, pathology, 
imaging, and microscopy.  Understanding its application to the diabetic mouse eye requires study of the 
pathogenesis of diabetic retinopathy and the basics of imaging and microscopy.  The following sections 
provide background in these areas. 
 
Diabetes and Diabetic Retinopathy 
Diabetes is a disease characterized by the bodys inability to produce insulin or utilize it 
efficiently.  There exist two forms of diabetes: type-1, also known as juvenile-onset or insulin-dependent 
diabetes mellitus, and type-2, also known as adult-onset or non-insulin dependent diabetes mellitus.  The 
greatest risk for complications, including diabetic retinopathy, exists in type-1 patients.  Major risk factors 
in complications include abnormalities in blood glucose and/or levels of insulin, usually resulting from 
poor glycemic control. 
Diabetic retinopathy is the most common microvascular complication of diabetes.  Within 20 
years of developing diabetes, more than 80% of type-1 patients have some degree of retinopathy.  The 
disease is the leading cause of blindness among Americans of working age. 
Diabetic retinopathy enters its earliest clinical stage when microaneurysms begin to form.  These 
abnormalities manifest themselves as minute bulges or outpouchings on the retinal capillaries.  Increased 
vascular permeability follows, reflecting an alteration in the blood-retinal barrier.  Fluid begins to 
accumulate in the retina at this stage, accompanied by hard exudates (yellow-white discrete patches of lipid 
that occur in rings around leaking capillaries) and cotton wool spots (areas of dense, scar-like tissue), 
resulting in obscured vision.  Ultimately, capillary nonperfusion, ischemia, and hypoxia result.   
In the proliferative stages of the disease, new blood vessels begin to grow, possibly induced by the 
ischemic/hypoxic state of the retina.  These new vessels are fenestrated capillaries and are thus extremely 
fragile and prone to hemorrhage.  The new vessels grow out of the retina and into the vitreous, causing 
vitreal scarring and shrinkage.  This traction pulls on the fragile new vessels, causing retinal traction, retinal 
tears, vitreous hemorrhage, and retinal detachment (which results in blindness).   
The pathogenesis of diabetic retinopathy is thought to be related to hypoxia.  It is not completely 
understood whether a change in oxygen consumption causes the alterations in vascular responses to 
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compensate for changes in blood flow, or if the changes in blood flow cause alterations in oxygen 
consumption.  However, it is understood that, by the time capillary closure and nonperfusion are clinically 
apparent, the retinal tissue is hypoxic, and the primary stimulus for neovascularization is hypoxia.   
The two most common treatments for diabetic retinopathy are vitrectomy and panretinal 
photocoagulation.  These are aimed at relieving hypoxia and slowing the neovascularization process, 
hopefully reducing the risk of visual loss.  The treatments tend to improve oxygenation in the ischemic and 
hypoxic retina.  Progression of diabetic retinopathy can often be prevented with good glycemic control of 
diabetic patients; the progress of the disease may be stopped in its very early stages if blood glucose is 
strictly regulated.  For all forms of treatment, early detection of the disease is essential; once the cascade of 
prolifereative retinopathy has begun, little can be done to save the sight of the patient.   
 Numerous animal models, including dogs, cats, rats, and mice, have been developed for diabetic 
retinopathy.  Mouse models for the disease have gained prominence due to the similarity between the 
human and mouse retinas, the relatively quick breeding time for mice, and the ease of working with these 
animals in a laboratory setting.  The ability to study the changes in oxygen tension in these diabetic mouse 
eyes will likely be of great benefit to diabetic retinopathy research. 
 
Phosphorescent Probe for Intravascular PO2 Measurements 
Light-emitting probes have received considerable attention in the literature as imaging aids.  
Chemicals that may be injected into the bloodstream, and that emit light when excited, have numerous 
implications for the study of blood vessels.  Additionally, the phosphorescent probe used in this study, 
palladium meso-tetra porphrine, has the favorable quality of being sensitive to oxygen molecules in the 
bloodstream. 
Phosphorescence is defined as the emission of light during a transition from an excited triplet state 
to the ground state. When a large number of phosphorescent molecules are excited simultaneously, the 
resultant total light emission can be represented by the function: 
 
I(t) = I0exp(-t/τ) 
 
where I(t) is the phosphorescence intensity as a function of time, I0 is the initial, maximum intensity at t = 
0, t is the time post-excitation, and τ is the lifetime of the decay. 
When the phosphorescent probe is excited by light that has been sinusoidally modulated, the 
phosphorescence emitted will have the same frequency, but will have lower amplitude and be delayed in 
phase by an angle θ.  θ is related to the probe lifetime by the following equation: 
 
tan θ = ωτ 
where ω is the excitation frequency. 
A phosphorescent molecule that has been excited to the triplet state may transfer its energy to 
another molecule without light emission, a phenomenon termed quenching.  Such interactions between 
phosphors and their environment are common; the spin-forbidden transition from the triplet state to the 
ground has a relatively long lifetime (on the order of ms), and increases the probability of contact between 
molecules.  In blood, the only significant quenching agent is oxygen.  The efficiency of phosphorescence 
quenching depends on the frequency of collision between the excited triplet state molecule and the 
quencher before the phosphor returns to the ground state, and is therefore dependent on the concentration of 
oxygen in the vicinity of the probe.  This relationship is represented by the Stern-Volmer equation for an 
oxygen-quenched probe: 
τo / τ = 1 + kQτ0[PO2] 
 
where kQ is the bimolecular rate constant (or quenching constant), and [PO2] is the oxygen concentration.  
In a zero oxygen environment, τ = τo and the lifetime is at a maximum.   
 
Phosphorescence Lifetime Imaging of Oxygen Tension 
Phosphorescence lifetime imaging requires a unique microscopic instrument (Figure 1).  An 
illuminating beam is emitted by a xenon arc lamp, sinusoidally modulated using an optical chopper, and 
filtered to 524±20 nm (the excitation wavelength of the phosphorescent probe used in this study) by a 
monochromator.  The light is then reflected down into the objective by a dichromatic mirror.  This light 
excites the phosphorescent molecules in the specimen to the triplet state, and phosphorescence is emitted 
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during the decay of the molecules back to their ground states.  This emitted light then passes straight 
through the dichromatic mirror to the CCD camera, which transmits the image to the PC-based image 
analysis system.   
 
Figure 1—The phosphorescence lifetime imaging system 
 
A phase-sensitive measure of the phosphorescence lifetime in the presence of oxygen is possible 
when the delivered excitation light and the sensitivity of the collection system (intensifier) are 
independently modulated and the phase relationship between these two elements is accurately varied.  
Intensity images (Figure 2) may then be taken with varying intensifier phase delays, and a graph of 
intensity versus phase delay may be constructed.   This graph may be used in conjunction with the 
following equation to determine the phosphorescence phase delay, θ: 
 
I(θD) = k[Pd]{1+  mDmcos(θ-θD)} 
 
where Ι(θD) is the intensity, k is a constant, [Pd] is the probe concentration, θD is the phase delay of the 
intensifier sensitivity, and m and mD  are parameters defined as: 
 
(1 + ω2τ2) -1/2 
 
for the excitation/emission and intensifier sinusoids, respectively.  A best-fit estimate for τ may then 
calculated using linear regression.  This value of τ may be used in the Stern-Volmer equation to calculate 
PO2 maps (Figure 2). 
 
 
Figure 2—Phosphorescence intensity image and PO2 map of the mouse retina 
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Methods and Results 
In Vitro System 
An in vitro system was designed and constructed to calibrate the probe prior to data collection and 
to determine approximate gain settings and exposure times required to produce acceptable oxygen maps 
(Figure 3).  The system includes a length of Tygon tubing, into which a solution consisting of albumin 
stock solution, NaCl, glucose, and probe is injected.  A peristaltic pump is used to circulate the fluid 
through the system.  The phosphorescent solution flows through an oxygenator used to apply gas mixtures 
with known oxygen concentrations.  Upon leaving the oxygenator, the solution then flows through a glass 
capillary tube situated under a microscope equipped with the phosphorescence lifetime imaging system.  
The phosphorescence lifetime is then measured as previously described, and a PO2 map is generated.   
Signal-to-noise ratios (SNR) were used to determine appropriate gain settings and exposure times 
for subsequent in vivo experiments.  A physiological oxygen concentration of 40 mm Hg (5% oxygen 
applied using the oxygenator) was applied to the probe solution.  Exposure times were tested at random in 
an attempt to achieve a maximal range of SNR for camera intensifier gain settings 10, 100, and 255.  
Exposure times yielding SNR of approximately 2 and approximately 225 were noted for each gain.  
  
 
Figure 3—In vitro phosphorescence lifetime imaging system 
 
Phosphoresce lifetime images were then taken at a range of ten exposure times equally spaced between the 
time yielding SNR ≈ 2 and the time yielding SNR ≈ 225.  R2 maps, which demonstrate the integrity of the 
fit between the phosphorescence intensity data and the equation I(θD) = k[Pd]{1+  mDmcos(θ-θD)}, were 
then created.  From these maps, the average R2 value for the entire capillary tube was determined.  These 
values were plotted versus SNR for each gain setting (Figure 4). 
These data indicate that a gain setting of 255 does not produce images with acceptable R2 values, 
regardless of the SNR.  Conversely, R2 values of greater than 0.9 were obtained with gain settings 10 and 
100 for all SNR > 50.  These results were verified in later experiments for a full range of physiological 
oxygen concentrations.  As a result, all subsequent experiments were conducted at gain settings between 10 
and 100.  Since the data indicate that all SNR > 50 yield similarly high R2 values, exposure times resulting 
in signal-to-noise ratios of 50 or less were used, thereby minimizing excitation light exposure.   
The correspondence between the PO2 values indicated by the map and those applied using the gas 
mixer and oxygenator was used to calibrate the system to provide accurate measures of PO2 within the 
vasculature.  It was discovered using the in vitro system that the data analysis program as it existed assigned 
different PO2 values to image sets taken with different gain settings and exposure times.  The identification 
of this problem allowed the adjustment of the program parameters and the production of accurate oxygen 
maps. 
 
In Vivo System 
Mice used in the study were handled according to the Institutional Animal Care and Use 
Committee protocols.  Mice were anesthetized with an avertin/saline solution and situated in a stereotaxic  
Oxygenator 
Peristaltic 
pump Glass capillary tube 
Direction 
of flow 
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Figure 4—Average R2 value versus SNR for gain settings 10, 100, and 255 
 
head holder to prevent movement during experimentation.  Mouse eyes were dilated, hydrated with an 
ophthalmic ointment, and shielded with a cover glass to allow observation of retinal vessels at the back of 
the eye.  A solution of Pd meso-Tetra (4-carboxyphenyl) Porphrine probe was injected into the femoral 
vein in the amount of 10 mg/kg.   
Gain and exposure time settings were determined in vivo using the in vitro experiments as a guide.  
SNR values were calculated using gain settings 10, 40, 70, and 100.  Quality of oxygen maps (determined 
by average R2 value) improved with SNR of up to about 15, after which quality remained constant.  When 
ranges of exposure times yielding SNR between three and 15 were used for each gain, it was determined 
that exposure times of greater than one second caused damage to the retinal vessels (indicated by lack of 
blood flow).   As such, a new range of exposure times resulting in SNR between three and 15 without 
exceeding one second was determined (Table 1).   
 
Gain setting Exposure time range (seconds) 
100 0.058 - 0.402 
70 0.15 - 0.79 
40 0.32 - 1.0 
10 0.4 - 1.0 
Table 1—Exposure times yielding a range of SNR between approximately 3 and 15, without 
exceeding 1.0 seconds 
 
Experiments were also conducted with repeated exposures of 0.23 seconds at gain 100 and 1.0 
seconds at gain 40.  Average PO2 was plotted versus accumulated light exposure, and it was determined 
that extended light exposure (greater than 1000 mJ/cm2) actually cause a decrease in vessel PO2.  Such 
decreases were not observed with shorter terms of light exposure. 
 
Conclusions 
 The phosphorescence lifetime imaging system may be used on the mouse eye with accurate and 
reliable results.  Gain settings between 10 and 100 will yield acceptable intensity images and oxygen maps.  
Exposure times have been determined for each gain setting.  Longer exposure times yield intensity images 
and maps of better qualityhowever, care must be taken not to exceed cumulative light exposure of 1000 
mJ/ cm2 over the course of the experiment due to the risk of retinal damage and decrease in retinal PO2.  If 
longer exposure times are necessary, power of excitation light must be decreased. 
 The phosphorescence lifetime imaging system will be used to study retinal oxygenation changes in 
mouse models of diabetic retinopathy.  Understanding the changes in oxygenation at different stages of this 
serious disease may assist in developing and administering treatments and cures.  The noninvasive nature 
of the technique makes its application to human patients a potential option.  Detection of hypoxia using 
phosphorescence lifetime imaging may allow for early detection and treatment of diabetic retinopathy, 
potentially preventing blindness.   
